source
- ADARx aims for $318 million IPO as TRexBio and Retension also fileADARx Pharmaceuticals, a siRNA biotech currently in Phase 3 trials, announced plans to raise roughly $318 million through an initial public offering. The company is joining other biotech firms suc…
- Alkermes' orexin agonist ALKS 7290 shows promise in early-stage ADHD trialAlkermes reported results from a Phase 1 study of its orexin agonist ALKS 7290, a drug class previously explored for rare sleep disorders. The trial enrolled adults with moderate to severe ADHD, a…